Data / Drug companies / Medical Purchasing Solutions, LLC
Medical Purchasing Solutions, LLC: 269 products in the FDA NDC directory, labeler code 71872
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Medical Purchasing Solutions, LLC (labeler code 71872) lists 269 products in the FDA National Drug Code Directory, covering 70 finished drugs by generic name. By type: 269 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 28, 2026.
The request: Watch Medical Purchasing Solutions, LLC (FDA labeler code 71872): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 71872
- Products in commercial distribution
- 269
- Packages
- 268
- Finished drugs by generic name
- 70
- Prescription products
- 269
- Over the counter products
- 0
- Controlled substance products
- Schedule III 2, Schedule IV 2
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- April 2, 1959
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 223 | 82.9% |
| New drug applications (NDA) | 41 | 15.2% |
| Other unapproved drugs | 3 | 1.1% |
| Authorized generics (NDA) | 2 | 0.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 269 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 141 | 52.4% |
| Injection | 96 | 35.7% |
| Injection, powder, for solution | 12 | 4.5% |
| Solution | 8 | 3% |
| Tablet | 6 | 2.2% |
| Injection, solution, concentrate | 3 | 1.1% |
| Injection, powder, lyophilized, for solution | 2 | 0.7% |
| Spray | 1 | 0.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sugammadex | 71872-7382 | Injection, solution | Generic drugs (ANDA) | July 28, 2026 |
| Sodium bicarbonate | 71872-7376 | Injection, solution | Generic drugs (ANDA) | August 7, 2025 |
| Lidocaine hydrochloride | 71872-7362 | Injection, solution | Generic drugs (ANDA) | July 1, 2025 |
| Diphenhydramine Hydrochloride | 71872-7373 | Injection | Generic drugs (ANDA) | June 30, 2025 |
| Magnesium Sulfate | 71872-7381 | Injection, solution | Generic drugs (ANDA) | May 28, 2025 |
| Procainamide Hydrochloride | 71872-7353 | Injection, solution | Generic drugs (ANDA) | January 15, 2025 |
| Famotidine | 71872-7366 | Injection, solution | Generic drugs (ANDA) | December 15, 2024 |
| Atropine Sulfate | 71872-7355 | Solution | Generic drugs (ANDA) | December 9, 2024 |
| Dexamethasone Sodium Phosphate | 71872-7347 | Injection, solution | Generic drugs (ANDA) | December 1, 2024 |
| Amiodarone Hydrochloride | 71872-7354 | Injection, solution | Generic drugs (ANDA) | October 31, 2024 |
| Ketorolac tromethamine | 71872-7363 | Injection, solution | Generic drugs (ANDA) | October 4, 2024 |
| Rocuronium bromide | 71872-7372 | Injection, solution | Generic drugs (ANDA) | October 3, 2024 |
| Nalbuphine hydrochloride | 71872-7331 | Injection | Generic drugs (ANDA) | September 26, 2024 |
| Nitroglycerin | 71872-7383 | Tablet | Generic drugs (ANDA) | September 1, 2024 |
| Furosemide | 71872-7350 | Injection | New drug applications (NDA) | August 19, 2024 |
| Neffy | 71872-7330 | Spray | New drug applications (NDA) | August 9, 2024 |
| Atropine Sulfate | 71872-7341 | Solution | Generic drugs (ANDA) | July 4, 2024 |
| Atropine Sulfate | 71872-7340 | Solution | Generic drugs (ANDA) | July 4, 2024 |
| Diltiazem Hydrochloride | 71872-7345 | Injection, solution | Generic drugs (ANDA) | June 1, 2024 |
| Vasopressin | 71872-7334 | Injection | Generic drugs (ANDA) | May 9, 2024 |
| Heparin Sodium | 71872-7352 | Injection | Generic drugs (ANDA) | April 1, 2024 |
| Heparin Sodium | 71872-7351 | Injection | Generic drugs (ANDA) | April 1, 2024 |
| Sodium bicarbonate | 71872-7371 | Injection, solution | Generic drugs (ANDA) | March 15, 2024 |
| Epinephrine | 71872-7360 | Injection | New drug applications (NDA) | March 7, 2024 |
| Nitroglycerin | 71872-7338 | Tablet | Generic drugs (ANDA) | December 5, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.